CVS Health Corp (CVS) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

CVS Health Corp (CVS)

97.37

+0.31 (0.32%)

as of Jun 10, 2026, 5:17:39 pm Market Open.

411 watching

Investor Insights

Jun 10, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

CVS Health Corp has seen a significant rise in its stock price, recently jumping 8% to reach a three-year high after beating earnings and raising its full-year forecast. Experts note that while the stock may appear cheap, caution is warranted as some underlying issues persist, particularly with visibility and execution. CVS is more than just a drug store chain; it is also a managed care company that is undergoing a transformation driven by strong leadership. Although the retail pharmacy space faces weaknesses, their health insurance segment is showing substantial improvement with notable revenue growth, leading to positive adjustments in guidance. Overall, CVS is viewed as a turnaround story that presents growth opportunities as competitors falter, and its valuation relative to earnings suggests that it may still have room to increase further.

Consensus

Positive

Valuation

Undervalued

Similar

MRK

PAST TOP PICK

(A Top Pick Jan 22/21, Up 46%) Trades at 13x earnings. Still a long way to go. He's very big on pharmacies, as they're delivering more and more services since it's cheaper than via hospitals.

Wealthica Track your Stocks in your Watch List

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 55.5%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CVS is progressing well. We now recommend trailing up the stop (from $82) to $95. If triggered, this would all but guarantee a net investment gain of 30%, when combined with our previous recommendation to cover half.

PAST TOP PICK

(A Top Pick Jan 19/21, Up 42%) Debt is manageable. Free cashflow of about 13B. Well capitalized. Insurance, pharmacy with HealthHub, pharmacy benefit manager. Not expensive at 13x earnings.

BUY

Has done well, raising estimates for 2022. Redefined itself, and the market's realizing it's more than just a drugstore. Centred around health wellness. Trades at 12x earnings. Good cashflow, decent dividend.

HOLD

The PE is still attractive. CVS is adding more health services in their drug stores. Covid vaccinations encourage consumers to buy more items in their stores when they visit. Still a hold and you'll get a decent return. Still some upside here.

Premium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

Recently selected as a top pick by both our research editor Michael O'Reilly and Chris Bulmas. Very successful during the pandemic. Social media mentions increased 538% these last 24h.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Nov 26/20, Up 37.69%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with CVS is progressing well. We recommend trailing up the stop (from $70) to $82. If triggered this would result in a net investment gain over 21%, when combined by our previous recommendation to cover half.

COMMENT

They report Wednesday. They've been a roll because of the Covid vaccine and superior execution compared to Walgreens. But can they continue their streak as the pandemic winds down? They do have a huge health insurance business.

Wealthica Track your Stocks in your Watch List

PAST TOP PICK

(A Top Pick Feb 26/20, Up 39%) He still likes it. It has a unique business model: a pharmacy, pharmacy benefit management (PBM) and health insurer. Pays a good dividend, diversified and trades around 10x earnings. Free-cash flow yield is almost 9%. It's a durable business.

BUY

It's cheap, and trades well below the market multiple. Booster shots will be a big benefit to CVS.

BUY

Vertically integrated, growing dynamically. CVS has health insurance with Aetna, pharmacy benefit manager with CareMark, and HealthHub offering in-store diagnostics. Better choice than WBA.

PAST TOP PICK

(A Top Pick Aug 21/20, Up 34%) Absolutely he'll stick with it. Trades at a fine PE. It's not just pharmacies but health insurance to add up to a vertical health business.

HOLD

WBA has operations in the US and UK. Stays in drug retail and expands geographically. Doesn't grow quickly, but it's not an income stock either. Growth profile not attractive. She owns CVS instead, with its vertically integrated strategy.

PAST TOP PICK

(A Top Pick Jun 29/20, Up 32%) They became big after buying Aetna. They're broadening offering within stores to offer services like nurse practitioners. They think beyond just being a drug store. They're well-positioned in their industry. Take a long-term view, but you can buy this at current prices.

BUY

He prefers CVS to WBA. WBA has spun its wheels a bit. CVS has better management, and it's vertically integrated with Aetna and its pharmacy benefit manager. As the pandemic eases, its revenues from Covid will shift to other areas, such as HealthHUB for chronic conditions.

Showing 151 to 165 of 464 entries

Most Recent Experts

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Barry Schwartz

Baskin Wealth Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Mike Vinokur, CFA, CMT, and CFP

Propellus Wealth Partners/iA Private Wealth

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

CVS Health Corp (CVS)